

1 **Reporting quality in systematic reviews of *in vitro* studies: a systematic**  
2 **review.**

3 **Short title:** *SR of reporting quality of SR of in vitro studies*

4 **Abdelrahman Elshafay**<sup>1,2</sup>, **Esraa Salah Omran**<sup>2,3</sup>, **Mariam Abdelkhalek**<sup>2,4</sup>, **Mohamed Omar El-**  
5 **Badry**<sup>1,2</sup>, **Heba Gamal Eisa**<sup>2,5</sup>, **Salma Y Fala**<sup>2,6</sup>, **Thao Dang**<sup>2,7</sup>, **Mohammad A.T. Ghanem**<sup>2,8</sup>,  
6 **Maha Elbadawy**<sup>2,9</sup>, **Mohamed Tamer Elhady**<sup>2,10</sup>, **Nguyen Lam Vuong**<sup>2,11</sup>, **Kenji Hirayama**<sup>12</sup>,  
7 **Nguyen Tien Huy**<sup>13,14,\*</sup>

8 <sup>1</sup>*Faculty of Medicine, Al-Azhar University, Cairo, 11884, Egypt*

9 <sup>2</sup>*Online Research Club (<http://www.onlineresearchclub.org/>)*

10 <sup>3</sup>*Kasralainy School of Medicine, Cairo University, Cairo, 11562, Egypt*

11 <sup>4</sup>*Teaching assistant at Microbiology and Immunology Department, Faculty of Medicine, Tanta*  
12 *University, Tanta, 31527, Egypt*

13 <sup>5</sup>*Faculty of Medicine, Menoufia University, Egypt*

14 <sup>6</sup>*Faculty of Medicine, Suez Canal University, Ismailia, Egypt*

15 <sup>7</sup>*Surgery Department, School of Medicine, Tan Tao University, 70000, Vietnam.*

16 <sup>8</sup>*Department of Vascular Surgery, Uniklinik Magdeburg, 39112, Germany.*

17 <sup>9</sup>*Ministry of Health, Egypt*

18 <sup>10</sup>*Department of Pediatrics, Zagazig University Hospitals, Faculty of Medicine, Sharkia, 44511, Egypt*

19 <sup>11</sup>*Department of Medical statistic and Informatics, Faculty of Public Health, University of Medicine*  
20 *and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam*

21 <sup>12</sup>*Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Graduate School of*  
22 *Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan*

23 <sup>13</sup>*Evidence Based Medicine Research Group & Faculty of Applied Sciences, Ton Duc Thang*  
24 *University, Ho Chi Minh City, Vietnam*

25 <sup>14</sup>*Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Leading*  
26 *Graduate School Program, and Graduate School of Biomedical Sciences, Nagasaki University,*  
27 *Nagasaki, Japan.*

28 \*Correspondence to:

29 *Nguyen Tien Huy*

30 [tienhuy@nagasaki-u.ac.jp](mailto:tienhuy@nagasaki-u.ac.jp) (ORCID: [0000-0002-9543-9440](https://orcid.org/0000-0002-9543-9440))

31

32 **Abstract**

33 **Background:** Systematic reviews (SRs) and/or meta-analyses of *in vitro* research play an  
34 important role in establishing the foundation for clinical studies. In this study, we aimed to  
35 evaluate the reporting quality of SRs of *in vitro* studies using PRISMA checklist.

36 **Method:** Four databases were searched including PubMed, Virtual Health Library (VHL),  
37 Web of Science (ISI), and Scopus. The search was limited from 2006 to 2016 to include all  
38 SR and/or MA of pure *in vitro* studies. The evaluation of reporting quality was done using the  
39 PRISMA checklist.

40 **Results:** Out of 7702 search results, 65 SRs were included and evaluated with PRISMA  
41 checklist. Overall, the mean overall quality score of reported items of PRISMA checklist was  
42 68%. We have noticed an increasing pattern of the numbers of the published SR of *in vitro*  
43 studies over the last ten years. In contrast, *the reporting quality was not significantly improved*  
44 *over the same period* ( $p = 0.363$ ). There was positive but not significant correlation between  
45 the overall quality score and the journal's impact factor of the included studies.

46 **Conclusions:** *The adherence of SRs of in vitro studies to the PRISMA guideline was poor;*  
47 *Therefore, we believe that using reporting guidelines and paying attention of journals to this*  
48 *fact will improve more the quality of SRs of in vitro studies.*

49 **Keywords:** Reporting quality; Systematic review; Meta-analysis; PRISMA; *in vitro*.

50

## 51 **Introduction**

52           In 1979, the Canadian Task Force on the Periodic Health Examination published  
53 recommendations about health examination based on medical research with the classification  
54 of the level of evidence [1]. Furthermore, in an article of Sackett et al about antithrombotic  
55 medications, the levels of evidence have become the cornerstone to building guidelines and  
56 clinical recommendations [2]. In the widely accepted hierarchy of evidence-based medicine  
57 described by Oxford Centre for Evidence-based Medicine, systematic reviews (SRs) and  
58 meta-analyses (MAs) were placed at the highest level in agreement with other grading  
59 systems [1, 2, 3]. SRs and MAs provide high-quality information to clinicians and scientists  
60 since they meticulously evaluate and analyze the whole body of evidence to answer a specific  
61 research question. These studies, however, can have detrimental flaws which might mislead  
62 physicians and scientists in their clinical practice or research. The two major factors  
63 considered in evaluating the thoroughness of the conduct of SRs are reporting quality and risk  
64 of bias assessment. Transparency in reporting design, conduct, and analysis of the studies will  
65 allow the scientific community to adequately identify limitations, increase the reproducibility  
66 of data, and judge the reliability of the findings. Therefore, reporting quality has called  
67 attention in different types of studies.

68           Although several reporting guidelines are available according to the study design, and  
69 are also enforced by some journals, the quality of reporting still has room for improvement  
70 [4, 5, 6, 7, 8, 9, 10, 11, 12]. [6, 12]. [7] [11]. [8, 9, 10]. The applicability of results from the  
71 poorly reported studies should be questioned. Overall, the transparency in the documentation  
72 of clinical studies has increased due to implementation of the reporting guidelines, a common  
73 agreement among authors and editors is still needed to improve the quality of reporting  
74 furthermore. In 1996, a scientific group developed a guidance called the QUOROM  
75 Statement (QUality Of Reporting Of Meta-analyses) for reporting meta-analysis [17]. After  
76 that a meeting in June 2005, was held to update QUOROM yielded in an international survey  
77 for review authors, consumers and groups use systematic review and meta-analysis. Survey's  
78 results were used to update QUOROM, which was renamed as PRISMA (Preferred Reporting  
79 Items for Systematic reviews and Meta-Analyses) [18]. The PRISMA checklist consists of a  
80 27-item and a four-phase flow diagram, which aims at improving the reporting of systematic  
81 reviews and meta-analyses.

82           Regarding *in vitro* studies, reporting quality is vital as well. Data from *in vitro*  
83 research establish the foundation on which clinical studies advance. Owning several high-tier  
84 journals, Nature Publishing Group set an example of good practice in maintaining reporting  
85 quality. The potential authors are requested to follow their checklist on reporting  
86 experimental design, statistics, describing agents, methods, data deposition policy, presenting  
87 electrophoresis, gel data, and other factors before submitting their papers [19]. Nature editors  
88 suggested additional guidelines for each type of study: Animals in Research: Reporting In  
89 Vivo Experiments (ARRIVE) for animal preclinical research, Reporting recommendations  
90 for tumor MARKer prognostic studies (REMARK) in studies on the biomarker, Biospecimen  
91 reporting for improved study quality (BRISQ) to describe biospecimen [20, 21, 22]. For  
92 SRs/MAs, although there are no specific reporting guidelines dedicated for SRs of *in vitro*  
93 studies, Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)  
94 became highly recommended for both clinical and preclinical fields [18, 23, 24]. Hence, we  
95 aimed to evaluate the reporting quality of *in vitro* SRs using the PRISMA tool, which  
96 includes critical reporting items for SRs.

97 .

## 98 **Methods**

### 99 *Search strategy*

100           Based on the recommendations of preferred reporting items for systematic reviews  
101 and meta-analyses (PRISMA) statement [18], this systematic review was conducted by  
102 searching four databases including Pubmed, Virtual Health Library (VHL), Web of Science,  
103 and Scopus. Search terms were "*in vitro*"[All Fields] AND ("systematic review"[All fields]  
104 OR "meta-analysis"[All fields] OR "meta-analysis"[Publication Type] OR ("Cochrane  
105 Database Syst Rev"[Journal] OR ("cochrane"[All Fields] AND "database"[All Fields] AND  
106 "syst"[All Fields] AND "rev"[All Fields]) OR "cochrane database syst rev"[All Fields])). The  
107 search was done on October 2016 and there were no restrictions but the publication date that  
108 was limited from 2006 to 2016.

### 109 *Selection criteria and data extraction*

110           We included all SRs and/or MAs of pure *in vitro* studies in which only *in vitro* studies  
111 were included. *In vitro* study was defined as the technique that is performed in controlled  
112 environment outside of a living organism. Excluding combined or *ex vivo* studies.

113 Independently, three reviewers assessed title and abstract of studies for commitment to  
114 eligibility criteria after duplicate removal using Endnote X7 program (Thompson Reuter,  
115 USA). One round of full-text screening was conducted by two or three independent reviewers  
116 to make sure that included studies meet the eligibility criteria. Data extraction from included  
117 papers was conducted in multiple rounds. At each round, three reviewers independently  
118 extracted data into an Excel sheet containing the items of PRISMA checklist. We also  
119 recoded the publication year, 2016 journal's impact factor (IF) where the included papers  
120 were published and It was extracted from the Web of Science database, country of the first  
121 authors, and a number of countries of all co-authors where applicable for each included study.  
122 Then, reviewers underwent discussion to resolve any conflict. The decision of screening and  
123 extraction was always taken by consensus of all reviewers and when a disagreement  
124 occurred, a consensus decision was reached after consulting with the supervisor (NTH).

#### 125 *Assessment of the reporting quality*

126 Eligible studies were evaluated with the Preferred Reporting Items for Systematic  
127 Reviews and Meta-Analyses (PRISMA) [25]. The PRISMA statement is a list of twenty-  
128 seven items that are recommended to ensure the reporting quality of systematic reviews. Each  
129 item is judged to be one of three responses we have developed to evaluate the adherence of  
130 each paper to the PRISMA guideline. These responses are “applicable and reported”,  
131 “applicable and not reported”, or “not applicable nor reported” response scored with (1), (0),  
132 and (NA) respectively. Applicable means that this item could be evaluated in the study. The  
133 overall quality score was calculated by dividing the total score of the applicable and reported  
134 items upon the number of applicable items. In the present study, each review was evaluated  
135 independently by three reviewers and the consensus was reached out after discussion. The  
136 supervisors (NTH, KH) were consulted when disagreement occurs.

#### 137 *Statistical analysis*

138 The evaluation of each item of PRISMA checklist was based on three responses;  
139 “applicable and reported”, “applicable and not reported”, or “not applicable nor reported”  
140 scored with (1), (0), and (NA) respectively. Statistical analyses were performed using the  
141 Statistical Package for the Social Sciences (version 22.0, SPSS Inc, Chicago, IL, USA).  
142 Regarding the responses, data were presented as median and interquartile range (IQR). Data  
143 were first analyzed for normality and decision were based on Shapiro-Wilk test result.  
144 Spearman's correlation test was used to test the correlation between the overall score and IF.

145 Univariable and multivariable logistic regression analyses were used to determine the association  
146 between PRISMA score and some important predictors, which included year of publication, presence  
147 of meta-analysis, and journal's impact factor. Linear regression was used to test the trend of  
148 overall score over the search period. The trend of the overall score and SR of *in vitro* studies  
149 over the publication year were presented in form of scatter plots. Two-tailed significance  
150 levels of  $< 0.05$  were considered to indicate statistical significance.

## 151 **Results**

### 152 *Study selection*

153 The search strategy identified 7702 potentially relevant records on 10<sup>th</sup> of October  
154 2016. After removal of duplicates, we had 7624 papers. After screening titles and abstracts,  
155 we retrieved 111 full-text papers for more detailed information. Finally, 65 papers met the  
156 eligibility criteria and were included in the review. Flow diagram summarizes the process of  
157 studies selection and the reasons for exclusions (Fig. 1).

### 158 *Study characteristics*

159 The publication period of the 65 eligible studies ranged from 2007 to 2016. All  
160 included studies were systematic reviews of *in vitro* studies published in the English  
161 language. The country of the first author was Brazil in 13 articles (21.5%), Netherlands in  
162 eight (12.3%), five articles (7.6%) for each of Iran and Canada, USA in four articles (6.1%),  
163 three articles (3%) for Italy, two articles for Switzerland, New Zealand, and China, and one  
164 article for each of Australia, Austria, Belgium, Brunei, Ghana, Germany, Greece, Indonesia,  
165 India, Israel, Jordan, Korea, Liechtenstein, Mexico, Norway, Saudi Arabia, Sweden,  
166 Slovenia, Portugal, Turkey, and UK. Study characteristics and result summary of the overall  
167 frequency of reporting items are in Table 1 and Table 2, respectively.

Table 1. Study characteristics of the included studies

Geographic distribution	Author/publication year	Country of the first author	Journal	IF (2016)	Score*
Europe	Boersema/2016 [26]	Netherlands	<u>BioResearch Open Access</u>	No IF	0.6
	van Heumen/2008 [27]	Netherlands	<u>Dental Materials</u>	3.93	0.68
	Snijder/2015 [28]	Netherlands	<u>Biomedizinische Technik</u>	No IF	0.65
	Louropoulou/2015 [29]	Netherlands	<u>Clinical Oral Implants Research</u>	3.46	0.95
	Montano/2010 [30]	Netherlands	<u>Toxicological Sciences</u>	1.22	0.5
	Dobbenga/2016 [31]	Netherlands	<u>Acta Biomaterialia</u>	6	0.5
	Behring/2008 [32]	Netherlands	Odontology	1.53	0.5
	Golbach/2016 [33]	Netherlands	Environment International	5.92	0.7
	Gizzo/2015 [34]	Italy	European Journal of Cancer Prevention	2.415	0.6
	Rotelli/2015 [35]	Italy	<u>Surgical Oncology</u>	3.65	0.43
	Salamanna/2016 [36]	Italy	Oncotarget	5	0.96
	Coray/2016 [37]	Switzerland	<u>Journal of the Mechanical Behavior of Biomedical Materials</u>	2.87	0.66
	Finnema/2010 [38]	Switzerland	<u>American Journal of Orthodontics and Dentofacial Orthopedics</u>	1.6	0.72
	Moreira/2015 [39]	Portugal	Clinical implant dentistry and related research	4.152	0.59
	Papia/2014 [40]	Sweden	<u>Journal of Biomedical Materials Research Part B: Applied Biomaterials</u>	2.881	0.56
	Bleuel/2015 [41]	Germany	PLoS ONE	4.41	0.63
	Napotnik/2016 [42]	Slovenia	Bioelectrochemistry	3.55	0.88
	Baumeister/2016 [43]	UK	Psychopharmacology (Berl)	3.54	0.78
	Tzanakakis/2016 [44]	Greece	Journal of Prosthetic Dentistry	NA	0.45
	Nilsen/2016 [45]	Norway	<u>European Journal of Oral Sciences</u>	1.6	0.59
Schmid-Schwap/2011 [46]	Austria	<u>Dental Materials</u>	3.93	0.62	
Bonczkowski/2016 [47]	Belgium	AIDS Reviews	2.06	0.54	
Heintze/2008 [48]	Liechtenstein	<u>Dental Materials</u>	3.93	0.64	
Asia	Shahrvan/2007 [49]	Iran	<u>Journal of Endodontics</u>	2.904	0.81
	Khalesi/2015 [50]	Iran	<u>Journal of Pediatric Gastroenterology and Nutrition</u>	2.4	0.62
	Samiei/2016 [51]	Iran	<i>Materials Science and Engineering C: Materials for Biological Applications</i>	3.42	0.6
	Motamedian/2015 [52]	Iran	<u>World Journal of Stem Cells</u>	No IF	0.52
	Tabatabaei-Malazy/2012 [53]	Iran	<u>Journal of Pharmacy &amp; Pharmaceutical Sciences</u>	2.33	0.54
	Ni/2015 [54]	China	<u>International Journal of Antimicrobial Agents</u>	4.09	0.74
	Xiao/2011 [55]	China	<u>American Journal of Nephrology</u>	2.6	0.68



	<b>Ilango/2015</b> [56]	India	International Journal of Current Pharmaceutical Review and Research	No IF	0.22
	<b>Rahman/2016</b> [57]	Brunei	Brain Research	2.56	0.68
	<b>AlShwaimi/2016</b> [58]	Saudi Arabia	<u>Journal of Endodontics</u>	2.9	0.7
	<b>Ahn/2016</b> [59]	Korea	<u>Journal of Endodontics</u>	2.9	0.63
	<b>Masarwa/2016</b> [60]	Jordan	<u>Journal of Evidence-Based Dental Practice</u>	No IF	0.69
	<b>Jayanegara/2014</b> [61]	Indonesia	<u>Asian-Australasian Journal of Animal Sciences</u>	0.75	0.59
	<b>Zusman/2013</b> [62]	Israel	<u>Antimicrobial Agents and Chemotherapy</u>	4.41	0.74
	<b>Yaylali/2015</b> [63]	Turkey	<u>Journal of Endodontics</u>	2.9	0.83
<b>South America</b>	<b>Lenzi/2016</b> [64]	Brazil	International Journal of Paediatric Dentistry	1.303	0.96
	<b>Altmann/2016</b> [65]	Brazil	<u>Orthodontics &amp; Craniofacial Research</u>	1.64	0.92
	<b>Pereiraa/2015</b> [66]	Brazil	Journal of the Mechanical Behavior of Biomedical Materials	2.876	0.81
	<b>de Rosa/2015</b> [67]	Brazil	<u>Journal of Dentistry</u>	3.109	0.81
	<b>Moraes/2015</b> [68]	Brazil	<u>Operative Dentistry</u>	2.819	0.85
	<b>Chaves/2012</b> [69]	Brazil	Journal of Prosthetic Dentistry	NA	0.73
	<b>Kaizer/2014</b> [70]	Brazil	<u>Dental Materials</u>	3.931	0.68
	<b>Aurelio/2016</b> [71]	Brazil	<u>Dental Materials</u>	3.931	0.81
	<b>Pavan/2015</b> [72]	Brazil	PLoS One	4.41	0.89
	<b>Bernades/2014</b> [73]	Brazil	<u>The Journal of the American Dental Association</u>	1.76	0.72
	<b>da Costa/2013</b> [74]	Brazil	<u>The Journal of Adhesive Dentistry</u>	1.59	0.62
	<b>Sarkis-Onofre/2014</b> [75]	Brazil	<u>Operative Dentistry</u>	2.81	0.92
<b>Skupien/2015</b> [76]	Brazil	Brazilian Oral Research	0.85	0.73	
<b>North America</b>	<b>Lee/2008</b> [77]	USA	Journal of Prosthetic Dentistry	NA	0.54
	<b>Bates/2015</b> [78]	USA	Clinical Biomechanics (Bristol, Avon)	1.636	0.59
	<b>Pasipanodya/2015</b> [79]	USA	Clinical Infectious Diseases	8.736	0.75
	<b>Arilla/2015</b> [80]	USA	Arthroscopy	3.7	0.92
	<b>Ting/2016</b> [81]	USA	<u>European Journal of Oral Sciences</u>	1.6	0.59
	<b>Nassar/2011</b> [82]	Canada	Journal of Prosthetic Dentistry	NA	0.63
	<b>Ehsani/2009</b> [83]	Canada	<u>The Angle Orthodontist</u>	1.5	0.72
	<b>Passos/2014</b> [84]	Canada	<u>Journal of Prosthodontics</u>	1.133	0.77
	<b>Archambault/2010</b> [85]	Canada	<u>The Angle Orthodontist</u>	1.2	0.72
	<b>Contreras-Ochoa/2012</b> [86]	Mexico	<u>Parasitology Research</u>	1.538	0.68
<b>Oceania</b>	<b>Tong/2015</b> [87]	New Zealand	<u>Human Reproduction Update</u>	11.194	0.77
	<b>Peplow/2013</b> [88]	New Zealand	Cytokine	2.94	0.63
	<b>Nawafleh/2016</b> [89]	Australia	<u>Journal of Prosthodontics</u>	1.133	0.6
<b>Africa</b>	<b>Fokou/2015</b> [90]	Ghana	<u>Journal of Ethnopharmacology</u>	3.05	0.5

169 \*Overall score was calculated as (total score of applicable and reported items/total score of applicable and reported & applicable and not  
170 reported items) to PRISMA statement  
171 IF 2016 was extracted from the Web of Science database.  
172 IF: impact factor; NA: no 2016 IF in the database for this journal.

173 **Table 2. Result summary of reported items of PRISMA checklist among the included 65 studies.**

<b>Items</b>	<b>Total number of applicable papers of each item, n (%)</b>	<b>Number of papers reporting that item, n (%)</b>
Title	65 [100]	58 [89.2]
Abstract	65 [100]	42 [64.6]
<b>Introduction</b>		
Rationale	65 [100]	65 [100]
Objectives	65 [100]	62 [95.4]
<b>Methodology</b>		
Protocol registration	65 [100]	4 [6.1]
Eligibility criteria	65 [100]	64 [98.5]
Information sources	65 [100]	64 [98.5]
Search	65 [100]	62 [95.4]
Study selection	65 [100]	59 [90.8]
Data collection	65 [100]	47 [72.3]
Data items	65 [100]	29 [44.6]
Risk of bias in individual studies	65 [100]	17 [26.2]
Summary measures	36 [55.3]	28 [77.7]
Synthesis of results	32 [49.2]	27 [84.3]
Risk of bias across Studies	65 [100]	13 [20]
Additional analysis	24 [36.9]	15 [62.5]
<b>Result</b>		
Study selection	65 [100]	58 [89.3]
Study characteristic	65 [100]	58 [89.3]
Risk of bias in individual studies	65 [100]	19 [29.2]
Results of individual studies	65 [100]	61 [93.8]
Synthesis of result	26 [40]	20 [76.9]
Risk of bias across studies	65 [100]	12 [18.5]
Additional analysis	20 [30.7]	12 [60]
<b>Discussion</b>		
Summary of evidence	65 [100]	63 [96.9]
Limitations	65 [100]	28 [43.1]
Conclusion	65 [100]	64 [98.5]
Funding	65 [100]	31 [47.7]

175 *Synthesis of the results*

176 ***Title and abstract***

177 Titles in 89.2% (58/65) of articles contained the terms "SR or MA". Structured  
178 abstract was reported in 64.6% (42/65) of applicable articles.

179 ***Introduction (objectives and rationale)***

180 All articles' introductions were found to be properly addressing the rationale item.  
181 The objectives item was reported in the majority of articles 95.4% (62/65). Three articles did  
182 not fulfill the PRISMA statement in reporting the objective items. One of them was found  
183 stating the objectives as reviewing new developments of the certain topic instead of providing  
184 an explicit statement of questions need to be addressed according to PRISMA statement  
185 requirements, as this article was published in world journal of stem cells which has no IF  
186 [52].

187 ***Methods items***

188 Contrary to PRISMA statement requirements of reporting the existence, web address  
189 and the registration number of articles' protocols, only four articles reported protocol and  
190 registration item representing 6.1% of included articles. Two papers were registered in  
191 Prospero database [64, 91] while the third papers provided the protocol as an appendix of  
192 their paper at the journal website [92]. In contrast, one paper reported having protocol but  
193 with no information about if it registered or not [33]. Most of the articles specified criteria  
194 for eligibility as study characteristics and report characteristics but only one article did not  
195 fulfill this item [56]. All authors reported the searched databases of peer-reviewed literature  
196 with addressing dates of coverage besides reporting using reference lists if done except one  
197 article.[56] For search and study selection items, most of the articles addressed it with 95.4%  
198 (62/65) and 90.8% (59/65), respectively. However, there was no standard statement for  
199 reporting the study selection item. We considered it fulfilled if authors used a flow diagram  
200 or explained this process as paragraph identifying how they retrieved or excluded papers in  
201 their reviews and if any disagreements were found and how they were resolved.

202 Data collection item was reported in 72.3% (47/65) of articles. However, less than  
203 half reported specific data items with 44.6% (29/65). The only fifth of papers has reported the  
204 risk of bias across studies item while about quarter of included articles have reported the risk  
205 of bias in the individual studies item. The summary measures and synthesis of results items

206 were reported widely with 77.7% (28/36) and 84.3% (27/32) of the applicable articles,  
207 respectively. Additional analysis of data deals with the further analysis of subgroups or  
208 meta-regression [25], it was found applicable and reported only in 62.5% (15/24) of the  
209 applicable articles.

### 210 ***Result items***

211 Concerning study selection item, most of the articles 89.3% (58/65) reported it in a  
212 paragraph or explained it with a flow diagram. They described clearly all screening process,  
213 the number of all screened studies, gave the reasons for exclusion of each. Then, they gave  
214 the number of the included studies that met the eligibility criteria and noted if there was a  
215 duplication. Meanwhile, most of the articles 89.3% (58/65) fully addressed study  
216 characteristics items in a table which included the study size, follow-up period and other  
217 specified characteristics. Reporting it provides a narrative summary of studies which allow  
218 the comparison between the main characteristic of the studies included in the review.

219 Only 29.2% (19/65) reported data on the risk of bias in each study and quality  
220 assessment for each of them while 18.5% (12/65) of the applicable articles reported the risk  
221 of bias across studies item. Reporting only summary data was inadequate because it failed to  
222 inform readers which studies had the particular methodological shortcoming. It was difficult  
223 for some of the included studies to assess the risk of bias because assessing the internal  
224 validity of a study requires adequate reporting of the study which was mostly poor and may  
225 require additional information from investigators as well. The synthesis of results and  
226 additional analysis items were reported in 76.9% (20/24) and 60% (12/20) of the applicable  
227 articles, respectively.

### 228 ***Discussion items***

229 Almost all articles 96.9% (63/65) reported the “summary of evidence” item. They  
230 summarized the main finding for each main outcome. Only two articles (3.1%) did not fulfill  
231 this item due to the poor quality of reporting. Less than half of the articles 43.1% (28/65)  
232 discussed the limitations at study and outcome level. This discussion addressed the validity of  
233 reporting of the included studies, the limitations of the review process and the generalizability  
234 of the review. The conclusion item was reported in almost all articles with 98.5% (64/65).  
235 While funding item was reported in only 47.7% (31/65) of applicable articles.

236 *Correlation and regression between the overall quality score and important factors*

Journal's IF of the fifty-six papers were reported (*Median*= 2.89, *IQR*= 2.29) and average overall quality score was (*M*= 0.68, *SD*= 0.14). Spearman's rho test indicated positive correlation but not significantly between the overall quality score and the IF,  $r = 0.209$  ( $p = 0.12$ ) (Figure 2). The uni- and multivariable analyses between PRISMA score and some important predictors, which included year of publication, presence of meta-analysis, and journal's impact factor, showed that only the presence of meta-analysis within the systematic review statistically affected to the PRISMA score. If a systematic review included meta-analysis, its PRISMA score would increase 0.08 points (95% CI: 0,011; 0.15) after adjusting for year of publication and journal's impact factor (Table 3).

246

**Table 3.** Association between PRISMA score and some important predictors through univariable and multivariable linear regression

249

Factor	Univariable linear analysis			Multivariable linear analysis		
	Coef.	95%CI	P value	Coef.	95%CI	P value
Year of publication	0.006	-0.008; 0.020	0.375	0.008	-0.006; 0.021	0.273
Presence of meta-analysis	<b>0.099</b>	<b>0.031; 0.167</b>	<b>0.005</b>	<b>0.080</b>	<b>0.011; 0.150</b>	<b>0.024</b>
Journal's impact factor	0.011	-0.009; 0.030	0.283	0.011	-0.008; 0.031	0.240

250

### Trend of SR of *in vitro* studies over the search period

The trend of published SR of *in vitro* studies was markedly increased over the period as shown in Figure 3A. Regression analysis revealed the trend of overall quality score was not significantly increasing over years (coefficient of correlation  $\beta = 0.11$ ,  $p = 0.363$ ) (Figure 3B).

### Agreement between three reviewers by each PRISMA's item

Among 27 items of PRISMA checklist, 12 items had the agreement of three reviewers which was 'almost perfect', i.e., the Kappa's index was above 0.90; 11 items had 'strong' agreement of three reviewers, i.e., the Kappa's index was in between 0.80 and 0.90. There were 4 items with 'moderate' agreement of three reviewers, i.e., the Kappa's index was in between 0.60 and 0.79 (Table 4).

262

Table 4. *Agreement between three reviewers by each PRISMA's item*

<b>Items</b>	<b>Kappa's index</b>	<b>Level of Agreement</b>
Title	1.000	Almost perfect
Abstract	0.908	Almost perfect
<b>Introduction</b>		
Rationale	1.000	Almost perfect
Objectives	0.870	Strong
<b>Methodology</b>		
Protocol registration	0.944	Almost perfect
Eligibility criteria	0.745	Moderate
Information sources	0.745	Moderate
Search	0.895	Strong
Study selection	0.942	Almost perfect
Data collection	0.901	Almost perfect
Data items	0.937	Almost perfect
Risk of bias in individual studies	0.900	Strong
Summary measures	0.900	Strong
Synthesis of results	0.982	Almost perfect
Risk of bias across Studies	0.746	Moderate
Additional analysis	0.887	Strong
<b>Result</b>		
Study selection	0.893	Strong
Study characteristic	1.000	Almost perfect
Risk of bias in individual studies	0.854	Strong
Results of individual studies	0.918	Almost perfect
Synthesis of result	0.891	Strong
Risk of bias across studies	0.843	Strong
Additional analysis	0.917	Almost perfect
<b>Discussion</b>		
Summary of evidence	0.651	Moderate
Limitations	0.895	Strong
Conclusion	1.000	Almost perfect
Funding	0.846	Strong

## 268 Discussion

269 In this systematic review, we used the PRISMA checklist to evaluate the reporting  
 270 quality of SRs of *in vitro* studies. Generally, the mean overall score of reported PRISMA

271 items was 68% which indicate a moderate adherence of SR of *in vitro* studies to PRISMA  
272 checklist. It was noticed also that the trend of published SR of *in vitro* studies was increased  
273 recently. There were eight items reported in less than 50% of the applicable studies, they  
274 included four items in the methodology section, two items in the results section and two  
275 items in discussion sections. Items of methodology section included 1) protocol registration  
276 with 6.1%, 2) data items with 44.6%, 3) risk of bias in individual studies with 26.2%, and 4)  
277 risk of bias across studies with 20% of applicable articles. In the results section, the risk of  
278 bias in individual and across studies items were associated with 29.2% and 18.5% of  
279 applicable articles, respectively. Finally, limitations and funding items in discussion section  
280 were associated with low reporting of 43.1% and 47.7%, respectively. Our result was quite  
281 similar to other reviews of reporting quality of SR of urology [93], orthopedic [94],  
282 acupuncture [95], diagnostic research [96], and other medical fields [97, 98, 99, 100]. The  
283 highest reporting quality was in SR of urology [93], while the lowest was in SR of burn care  
284 management [100].

285 Protocol registration is the most unfulfilled item of PRISMA checklist although  
286 registration becomes more common. In an SR on reporting quality of SRs in vascular  
287 surgery, Tan et al reported only one out of 74 articles mentioning this item [101].  
288 Registration can help eliminate the waste of conducting several SRs which address the same  
289 research question and reduce post hoc bias associated with selective outcome reporting [18].  
290 Therefore, data has shown a positive association between protocol registration and quality of  
291 that SR/MA of studies in pediatric surgery [97].

292 The risk of bias of individual studies and across studies, data items, limitations,  
293 funding, and additional analysis are other under-reported items in this SR, as in other SRs of  
294 clinical studies [100, 102]. The accuracy of findings from SRs depends on the reliability of  
295 included studies, which can include research with poor methodological quality in meta-  
296 analysis and mislead the results. Listing and defining all variables, describing methods of  
297 additional analyses, as well as discussing limitations are also important to improve the  
298 transparency of SR. Last but not least, financial disclosure should be mandatory for every  
299 kind of research, including SR. Several authors observed that the results of studies are more  
300 likely to favor the sponsor's products, exaggerate effects, and conceal harms [18].

301 Reviewers have found only five items from PRISMA statement that are "not  
302 applicable and not reported". They included Summary Measures, Synthesis of Results and



303 Additional Analysis from methodology section and Risk of Bias Across studies and  
304 Additional Analysis from results section. In sum, it appears that there are more SRs being  
305 published in basic sciences and preclinical research, yet their reporting quality remains a  
306 concern. PRISMA guideline was found to have potential limitations and be more generic in  
307 use instead of being standardized to various review types and it is not sufficient to evaluate  
308 the reporting quality if it used alone[103]. Therefore, Meta-analysis Of Observational Studies  
309 in Epidemiology (MOOSE) guideline was found to be more detailed and reach the depth of  
310 evaluating the reporting quality and it was recommended to use both in the epidemiological  
311 reviews[103]. In this systematic review, we have faced several limitations. First, the  
312 limitation of our study to a certain range of publication year and study design might lead to  
313 missing some valuable data either before the limited years or in combined *in vitro* and *in vivo*  
314 studies. Second, we could not able to register our protocol in PROSPERO databases as they  
315 did not accept of *in vitro* studies. Third, the analysis revealed no significant increase of the  
316 trend of overall quality score over the year and that may be because of small sample size  
317 which is not enough to detect a significant increase. Thus, more *in vitro* studies are warranted  
318 to achieve that. Finally, more attention and evaluation should be done for the various *in vitro*  
319 techniques in order to know the reporting quality of each subset which we could not able to  
320 evaluate that in our paper.

## 321 **Conclusion**

322 *The adherence of SRs of in vitro studies to the PRISMA guideline was less than*  
323 *optimal; Therefore, we believe that using reporting guidelines and paying attention of*  
324 *journals to this fact will improve more the quality of SRs of in vitro studies. Although, there*  
325 *are several items of PRISMA guideline that do not fit the designing and reporting of SRs of in*  
326 *vitro studies, it can be used until it gets improved. In addition, more attention should be paid*  
327 *to develop specific guideline to SRs of in vitro studies.*

## 328 **Acknowledgments/Funding**

329 This study was not supported by any funder.

## 330 **Conflict of interest**

331 None.

## 332 **References**

- 333 1. The periodic health examination. Canadian Task Force on the Periodic Health Examination.  
334 Can Med Assoc J. 1979;121(9):1193-1254.
- 335 2. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic  
336 agents. Chest. 1989;95:2s-4s.
- 337 3. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical  
338 decisions. Ann Intern Med. 1997;126:376-380.
- 339 4. Groenwold RH, Van Deursen AM, Hoes AW, et al. Poor quality of reporting confounding bias  
340 in observational intervention studies: a systematic review. Ann Epidemiol. 2008;18:746-751.
- 341 5. Elm EV, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies  
342 in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS  
343 Med. 2007;4(10):e296.
- 344 6. Bastuji-Garin S, Sbidian E, Gaudy-Marqueste C, et al. Impact of STROBE Statement  
345 Publication on Quality of Observational Study Reporting: Interrupted Time Series versus  
346 Before-After Analysis. PLoS One. 2013;8(8):e64733.
- 347 7. Bossuyt PM, Reitsma JB. The STARD initiative. Lancet 2003;361(71).
- 348 8. Fidalgo BM, Crabb DP, Lawrenson JG. Methodology and reporting of diagnostic accuracy  
349 studies of automated perimetry in glaucoma: evaluation using a standardised approach.  
350 Ophthalmic Physiol Opt. 2015;35(3):315-23.
- 351 9. Korevaar DA, Cohen JF, Hooft L, et al. Literature survey of high-impact journals revealed  
352 reporting weaknesses in abstracts of diagnostic accuracy studies. J Clin Epidemiol.  
353 2015;68:708-715.
- 354 10. Korevaar DA, van Enst WA, Spijker R, et al. Reporting quality of diagnostic accuracy studies: a  
355 systematic review and meta-analysis of investigations on adherence to STARD. Evid Based  
356 Med. 2014;19(2):47-54.
- 357 11. Korevaar DA, Wang J, van Enst WA, et al. Reporting Diagnostic Accuracy Studies: Some  
358 Improvements after 10 Years of STARD. Radiology 2015;274(3):781-789.
- 359 12. Rao A, Brück K, Methven S, et al. Quality of Reporting and Study Design of CKD Cohort  
360 Studies Assessing Mortality in the Elderly Before and After STROBE: A Systematic Review.  
361 PLoS One. 2016;11(5):e0155078.
- 362 13. Nojomi M, Ramezani M, Ghafari-Anvar A. Quality of reports on randomized controlled trials  
363 published in Iranian journals: application of the new version of consolidated standards of  
364 reporting trials (CONSORT). Arch Iran Med. 2013;16:20-22.
- 365 14. Ntala C, Bimpili P, Worth A, et al. The quality of reporting of randomised controlled trials in  
366 asthma: a systematic review. Prim Care Respir J. 2013;22(4):417-24.
- 367 15. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for  
368 reporting parallel group randomised trials. PLoS medicine 2010;7:e1000251.
- 369 16. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials  
370 (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs)  
371 published in medical journals. Cochrane Database Syst Rev. 2012;11:MR000030.
- 372 17. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of  
373 randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-  
374 analyses. Lancet. 1999;354(9193):1896-900.
- 375 18. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and  
376 meta-analyses: the PRISMA statement. PLoS medicine. 2009;6:e1000097.
- 377 19. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing  
378 risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928. PubMed  
379 PMID: 22008217; PubMed Central PMCID: PMC3196245.
- 380 20. Kilkeny C, Browne WJ, Cuthill IC, et al. Improving bioscience research reporting: the ARRIVE  
381 guidelines for reporting animal research. PLoS biology. 2010;8:e1000412.
- 382 21. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour  
383 MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387-391.

- 384 22. Moore HM, Kelly A, Jewell SD, et al. Biospecimen Reporting for Improved Study Quality  
385 (BRISQ). *J Proteome Res* 2012;10(8):3429-3438.
- 386 23. Fleming PS, Koletsis D, Seehra J, et al. Systematic reviews published in higher impact clinical  
387 journals were of higher quality. *J Clin Epidemiol.* 2014;67:754-759.
- 388 24. Zorzela L, Golder S, Liu Y, et al. Quality of reporting in systematic reviews of adverse events:  
389 systematic review. *BMJ.* 2014;348:f7668.
- 390 25. Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews  
391 and meta-analyses of studies that evaluate healthcare interventions: explanation and  
392 elaboration. *BMJ.* 2009;21(339):b2700.
- 393 26. Boersema GS, Grotenhuis N, Bayon Y, et al. The Effect of Biomaterials Used for Tissue  
394 Regeneration Purposes on Polarization of Macrophages. *Biores Open Access.* 2016;5(1):6-14.  
395 doi: 10.1089/biores.2015.0041.
- 396 27. van Heumen CC, Kreulen CM, Bronkhorst EM, et al. Fiber-reinforced dental composites in  
397 beam testing. *Dent Mater.* 2008 Nov;24(11):1435-43. doi: 10.1016/j.dental.2008.06.006.  
398 PubMed PMID: 18692230.
- 399 28. Snijder RA, Konings MK, Lucas P, et al. Flow variability and its physical causes in infusion  
400 technology: a systematic review of in vitro measurement and modeling studies. *Biomed Tech*  
401 (Berl). 2015 Aug;60(4):277-300. doi: 10.1515/bmt-2014-0148. PubMed PMID: 26352348.
- 402 29. Louropoulou A, Slot DE, Van der Weijden F. Influence of mechanical instruments on the  
403 biocompatibility of titanium dental implants surfaces: a systematic review. *Clin Oral Implants*  
404 *Res.* 2015 Jul;26(7):841-50. doi: 10.1111/clr.12365. PubMed PMID: 24641774.
- 405 30. Montano M, Bakker EJ, Murk AJ. Meta-analysis of supramaximal effects in in vitro  
406 estrogenicity assays. *Toxicol Sci.* 2010 Jun;115(2):462-74. doi: 10.1093/toxsci/kfq056.  
407 PubMed PMID: 20176621.
- 408 31. Dobbenga S, Fratila-Apachitei LE, Zadpoor AA. Nanopattern-induced osteogenic  
409 differentiation of stem cells - A systematic review. *Acta Biomater.* 2016 Dec;46:3-14. doi:  
410 10.1016/j.actbio.2016.09.031. PubMed PMID: 27667018.
- 411 32. Behring J, Junker R, Walboomers XF, et al. Toward guided tissue and bone regeneration:  
412 morphology, attachment, proliferation, and migration of cells cultured on collagen barrier  
413 membranes. A systematic review. *Odontology.* 2008 Jul;96(1):1-11. doi: 10.1007/s10266-  
414 008-0087-y. PubMed PMID: 18661198.
- 415 33. Golbach LA, Portelli LA, Savelkoul HF, et al. Calcium homeostasis and low-frequency  
416 magnetic and electric field exposure: A systematic review and meta-analysis of in vitro  
417 studies. *Environ Int.* 2016;92-93:695-706. doi: 10.1016/j.envint.2016.01.014.
- 418 34. Gizzo S, Noventa M, Di Gangi S, et al. Could in-vitro studies on Ishikawa cell lines explain the  
419 endometrial safety of raloxifene? Systematic literature review and starting points for future  
420 oncological research. *Eur J Cancer Prev* 2015;24(6):497-507. doi:  
421 10.1097/CEJ.000000000000107.
- 422 35. Rotelli MT, Bocale D, De Fazio M, et al. IN-VITRO evidence for the protective properties of  
423 the main components of the Mediterranean diet against colorectal cancer: A systematic  
424 review. *Surg Oncol.* 2015 Sep;24(3):145-52. doi: 10.1016/j.suronc.2015.08.001. PubMed  
425 PMID: 26303826.
- 426 36. Salamanna F, Contartese D, Maglio M, et al. A systematic review on in vitro 3D bone  
427 metastases models: A new horizon to recapitulate the native clinical scenario? *Oncotarget.*  
428 2016;7(28):44803-44820.
- 429 37. Coray R, Zeltner M, Ozcan M. Fracture strength of implant abutments after fatigue testing: A  
430 systematic review and a meta-analysis. *J Mech Behav Biomed Mater.* 2016 Sep;62:333-46.  
431 doi: 10.1016/j.jmbbm.2016.05.011. PubMed PMID: 27239815.
- 432 38. Finnema KJ, Ozcan M, Post WJ, et al. In-vitro orthodontic bond strength testing: a systematic  
433 review and meta-analysis. *Am J Orthod Dentofacial Orthop.* 2010 May;137(5):615-622 e3.  
434 doi: 10.1016/j.ajodo.2009.12.021. PubMed PMID: 20451780.

- 435 39. Moreira AH, Rodrigues NF, Pinho AC, et al. Accuracy Comparison of Implant Impression  
436 Techniques: A Systematic Review. *Clin Implant Dent Relat Res*. 2015 Oct;17 Suppl 2:e751-64.  
437 doi: 10.1111/cid.12310. PubMed PMID: 25828851.
- 438 40. Papias E, Larsson C, du Toit M, et al. Bonding between oxide ceramics and adhesive cement  
439 systems: a systematic review. *J Biomed Mater Res B Appl Biomater*. 2014 Feb;102(2):395-  
440 413. doi: 10.1002/jbm.b.33013. PubMed PMID: 24123837.
- 441 41. Bleuel J, Zaucke F, Bruggemann GP, et al. Effects of cyclic tensile strain on chondrocyte  
442 metabolism: a systematic review. *PLoS One*. 2015;10(3):e0119816. doi:  
443 10.1371/journal.pone.0119816. PubMed PMID: 25822615; PubMed Central PMCID:  
444 PMC4379081.
- 445 42. Batista Napotnik T, Rebersek M, Vernier PT, et al. Effects of high voltage nanosecond electric  
446 pulses on eukaryotic cells (in vitro): A systematic review. *Bioelectrochemistry*. 2016  
447 Aug;110:1-12. doi: 10.1016/j.bioelechem.2016.02.011. PubMed PMID: 26946156.
- 448 43. Baumeister D, Ciufolini S, Mondelli V. Effects of psychotropic drugs on inflammation:  
449 consequence or mediator of therapeutic effects in psychiatric treatment?  
450 *Psychopharmacology (Berl)*. 2016 May;233(9):1575-89. doi: 10.1007/s00213-015-4044-5.  
451 PubMed PMID: 26268146.
- 452 44. Tzanakakis EG, Tzoutzas IG, Koidis PT. Is there a potential for durable adhesion to zirconia  
453 restorations? A systematic review. *J Prosthet Dent*. 2016 Jan;115(1):9-19. doi:  
454 10.1016/j.prosdent.2015.09.008. PubMed PMID: 26548872.
- 455 45. Nilsen BW, Ortengren U, Simon-Santamaria J, et al. Methods and terminology used in cell-  
456 culture studies of low-dose effects of matrix constituents of polymer resin-based dental  
457 materials. *Eur J Oral Sci*. 2016 Dec;124(6):511-525. doi: 10.1111/eos.12309. PubMed PMID:  
458 27711994.
- 459 46. Schmid-Schwap M, Graf A, Preinerstorfer A, et al. Microleakage after thermocycling of  
460 cemented crowns--a meta-analysis. *Dent Mater*. 2011 Sep;27(9):855-69. doi:  
461 10.1016/j.dental.2011.05.002. PubMed PMID: 21703673.
- 462 47. Bonczkowski P, De Scheerder MA, De Spiegelaere W, et al. Minimal Requirements for  
463 Primary HIV Latency Models Based on a Systematic Review. *AIDS Rev*. 2016;18(4):171-183.
- 464 48. Heintze SD, Cavalleri A, Forjanic M, et al. Wear of ceramic and antagonist--a systematic  
465 evaluation of influencing factors in vitro. *Dent Mater*. 2008 Apr;24(4):433-49. doi:  
466 10.1016/j.dental.2007.06.016. PubMed PMID: 17720238.
- 467 49. Shahravan A, Haghdoost AA, Adl A, et al. Effect of smear layer on sealing ability of canal  
468 obturation: a systematic review and meta-analysis. *J Endod*. 2007;33(2):96-105.
- 469 50. Khaledi M, Jafari SA, Kiani M, et al. In Vitro Gluten Challenge Test for Celiac Disease  
470 Diagnosis. *J Pediatr Gastroenterol Nutr*. 2016 Feb;62(2):276-83. doi:  
471 10.1097/MPG.0000000000000917. PubMed PMID: 26196202.
- 472 51. Samiei M, Farjami A, Dizaj SM, et al. Nanoparticles for antimicrobial purposes in  
473 Endodontics: A systematic review of in vitro studies. *Mater Sci Eng C Mater Biol Appl*. 2016  
474 Jan 01;58:1269-78. doi: 10.1016/j.msec.2015.08.070. PubMed PMID: 26478430.
- 475 52. Motamedian SR, Hosseinpour S, Ahsaie MG, et al. Smart scaffolds in bone tissue  
476 engineering: A systematic review of literature. *World J Stem Cells*. 2015 Apr 26;7(3):657-68.  
477 doi: 10.4252/wjsc.v7.i3.657. PubMed PMID: 25914772; PubMed Central PMCID:  
478 PMC4404400.
- 479 53. Tabatabaei-Malazy O, Larijani B, Abdollahi M. A systematic review of in vitro studies  
480 conducted on effect of herbal products on secretion of insulin from Langerhans islets. *J*  
481 *Pharm Pharm Sci*. 2012;15(3):447-66.
- 482 54. Ni W, Shao X, Di X, et al. In vitro synergy of polymyxins with other antibiotics for  
483 *Acinetobacter baumannii*: a systematic review and meta-analysis. *Int J Antimicrob Agents*.  
484 2015;45(1):8-18. doi: 10.1016/j.ijantimicag.2014.10.002.

- 485 55. Xiao Z, Li C, Shan J, et al. Mechanisms of renal cell apoptosis induced by cyclosporine A: a  
486 systematic review of in vitro studies. *Am J Nephrol*. 2011;33(6):558-66. doi:  
487 10.1159/000328584. PubMed PMID: 21613783.
- 488 56. Ilango KB, Kavimani S. A systematic review of mathematical models of pharmaceutical  
489 dosage forms. *Int J Curr Pharm Rev Res*. 2015;6(1):59-70.
- 490 57. Rahman NA, Rasil AN, Meyding-Lamade U, et al. Immortalized endothelial cell lines for in  
491 vitro blood-brain barrier models: A systematic review. *Brain Res*. 2016 Jul 01;1642:532-45.  
492 doi: 10.1016/j.brainres.2016.04.024. PubMed PMID: 27086967.
- 493 58. AlShwaimi E, Bogari D, Ajaj R, et al. In Vitro Antimicrobial Effectiveness of Root Canal Sealers  
494 against *Enterococcus faecalis*: A Systematic Review. *J Endod*. 2016 Nov;42(11):1588-1597.  
495 doi: 10.1016/j.joen.2016.08.001. PubMed PMID: 27623499.
- 496 59. Ahn SY, Kim HC, Kim E. Kinematic Effects of Nickel-Titanium Instruments with Reciprocating  
497 or Continuous Rotation Motion: A Systematic Review of In Vitro Studies. *J Endod*. 2016  
498 Jul;42(7):1009-17. doi: 10.1016/j.joen.2016.04.002. PubMed PMID: 27185740.
- 499 60. Masarwa N, Mohamed A, Abou-Rabii I, et al. Longevity of Self-etch Dentin Bonding  
500 Adhesives Compared to Etch-and-rinse Dentin Bonding Adhesives: A Systematic Review. *J*  
501 *Evid Based Dent Pract*. 2016 Jun;16(2):96-106. doi: 10.1016/j.jebdp.2016.03.003. PubMed  
502 PMID: 27449836.
- 503 61. Jayanegara A, Wina E, Takahashi J. Meta-analysis on Methane Mitigating Properties of  
504 Saponin-rich Sources in the Rumen: Influence of Addition Levels and Plant Sources. *Asian-*  
505 *Australas J Anim Sci*. 2014 Oct;27(10):1426-35. doi: 10.5713/ajas.2014.14086. PubMed  
506 PMID: 25178294; PubMed Central PMCID: PMC4150175.
- 507 62. Zusman O, Avni T, Leibovici L, et al. Systematic review and meta-analysis of in vitro synergy  
508 of polymyxins and carbapenems. *Antimicrob Agents Chemother*. 2013;57(10):5104-11.
- 509 63. Ethem Yaylali I, Kececi AD, Ureyen Kaya B. Ultrasonically Activated Irrigation to Remove  
510 Calcium Hydroxide from Apical Third of Human Root Canal System: A Systematic Review of  
511 In Vitro Studies. *J Endod*. 2015 Oct;41(10):1589-99. doi: 10.1016/j.joen.2015.06.006.  
512 PubMed PMID: 26238527.
- 513 64. Lenzi TL, Gimenez T, Tedesco TK, et al. Adhesive systems for restoring primary teeth: a  
514 systematic review and meta-analysis of in vitro studies. *Int J Paediatr Dent*. 2016;26(5):364-  
515 75. doi: 10.1111/ipd.12210.
- 516 65. Altmann AS, Collares FM, Leitune VC, et al. The effect of antimicrobial agents on bond  
517 strength of orthodontic adhesives: a meta-analysis of in vitro studies. *Orthod Craniofac Res*.  
518 2016;19(1):1-9. doi: 10.1111/ocr.12100.
- 519 66. Pereira GK, Venturini AB, Silvestri T, et al. Low-temperature degradation of Y-TZP ceramics: A  
520 systematic review and meta-analysis. *J Mech Behav Biomed Mater*. 2015 Mar;55:151-63.  
521 doi: 10.1016/j.jmbbm.2015.10.017. PubMed PMID: 26590908.
- 522 67. Rosa WL, Piva E, Silva AF. Bond strength of universal adhesives: A systematic review and  
523 meta-analysis. *J Dent*. 2015 Jul;43(7):765-76. doi: 10.1016/j.jdent.2015.04.003. PubMed  
524 PMID: 25882585.
- 525 68. Moraes AP, Sarkis-Onofre R, Moraes RR, et al. Can Silanization Increase the Retention of  
526 Glass-fiber posts? A Systematic Review and Meta-analysis of In Vitro Studies. *Operative*  
527 *Dentistry*. 2015;40(6):567-580. doi: 10.2341/14-330-o.
- 528 69. Chaves CA, Machado AL, Vergani CE, et al. Cytotoxicity of denture base and hard chairside  
529 reline materials: a systematic review. *J Prosthet Dent*. 2012;107(2):114-27. doi:  
530 10.1016/S0022-3913(12)60037-7.
- 531 70. Kaizer MR, de Oliveira-Ogliari A, Cenci MS, et al. Do nanofill or submicron composites show  
532 improved smoothness and gloss? A systematic review of in vitro studies. *Dent Mater*  
533 2014;30(4):e41-78. doi: 10.1016/j.dental.2014.01.001.

- 534 71. Aurélio IL, Marchionatti AM, Montagner AF, et al. Does air particle abrasion affect the  
535 flexural strength and phase transformation of Y-TZP? A systematic review and meta-analysis.  
536 Dent Mater. 2016;32(6):827-45. doi: 10.1016/j.dental.2016.03.021.
- 537 72. Pavan LM, Rego DF, Elias ST, et al. In vitro Anti-Tumor Effects of Statins on Head and Neck  
538 Squamous Cell Carcinoma: A Systematic Review. PLoS One. 2015;10(6):e0130476. doi:  
539 10.1371/journal.pone.0130476. PubMed PMID: 26098683; PubMed Central PMCID:  
540 PMC4476585.
- 541 73. Bernades Kde O, Hilgert LA, Ribeiro AP, et al. The influence of hemostatic agents on dentin  
542 and enamel surfaces and dental bonding: a systematic review. J Am Dent Assoc. 2014  
543 Nov;145(11):1120-8. doi: 10.14219/jada.2014.84. PubMed PMID: 25359643.
- 544 74. da Costa DC, Coutinho M, de Sousa AS, et al. A meta-analysis of the most indicated  
545 preparation design for porcelain laminate veneers. J Adhes Dent. 2013 Jun;15(3):215-20. doi:  
546 10.3290/j.jad.a29587. PubMed PMID: 23593640.
- 547 75. Sarkis-Onofre R, Skupien JA, Cenci MS, et al. The role of resin cement on bond strength of  
548 glass-fiber posts luted into root canals: a systematic review and meta-analysis of in vitro  
549 studies. Oper Dent. 2014 Jan-Feb;39(1):E31-44. doi: 10.2341/13-070-LIT. PubMed PMID:  
550 23937401.
- 551 76. Skupien JA, Sarkis-Onofre R, Cenci MS, et al. A systematic review of factors associated with  
552 the retention of glass fiber posts. Braz Oral Res. 2015;29. doi: 10.1590/1807-3107BOR-  
553 2015.vol29.0074. PubMed PMID: 26083089.
- 554 77. Lee H, So JS, Hochstedler JL, et al. The accuracy of implant impressions: A systematic review.  
555 The Journal of Prosthetic Dentistry. 2008;100(4):285-291. doi: 10.1016/s0022-  
556 3913(08)60208-5.
- 557 78. Bates NA, Myer GD, Shearn JT, et al. Anterior cruciate ligament biomechanics during robotic  
558 and mechanical simulations of physiologic and clinical motion tasks: a systematic review and  
559 meta-analysis. Clin Biomech (Bristol, Avon). 2015 Jan;30(1):1-13. doi:  
560 10.1016/j.clinbiomech.2014.12.006. PubMed PMID: 25547070; PubMed Central PMCID:  
561 PMC4298459.
- 562 79. Pasipanodya JG, Nueremberger E, Romero K, et al. Systematic Analysis of Hollow Fiber Model  
563 of Tuberculosis Experiments. Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S10-7. doi:  
564 10.1093/cid/civ425. PubMed PMID: 26224767.
- 565 80. Arilla FV, Yeung M, Bell K, et al. Experimental Execution of the Simulated Pivot-Shift Test: A  
566 Systematic Review of Techniques. Arthroscopy. 2015 Dec;31(12):2445-54 e2. doi:  
567 10.1016/j.arthro.2015.06.027. PubMed PMID: 26321110.
- 568 81. Ting M, Whitaker EJ, Albandar JM. Systematic review of the in vitro effects of statins on oral  
569 and perioral microorganisms. Eur J Oral Sci. 2016 Feb;124(1):4-10. doi: 10.1111/eos.12239.  
570 PubMed PMID: 26718458.
- 571 82. Nassar U, Aziz T, Flores-Mir C. Dimensional stability of irreversible hydrocolloid impression  
572 materials as a function of pouring time: a systematic review. J Prosthet Dent.  
573 2011;106(2):126-33. doi: 10.1016/S0022-3913(11)60108-X.
- 574 83. Ehsani S, Mandich MA, El-Bialy TH, et al. Frictional resistance in self-ligating orthodontic  
575 brackets and conventionally ligated brackets. A systematic review. Angle Orthod. 2009  
576 May;79(3):592-601. doi: 10.2319/060208-288.1. PubMed PMID: 19413397.
- 577 84. Passos SP, Torrealba Y, Major P, et al. In vitro wear behavior of zirconia opposing enamel: a  
578 systematic review. J Prosthodont. 2014 Dec;23(8):593-601. doi: 10.1111/jopr.12167.  
579 PubMed PMID: 24957813.
- 580 85. Archambault A, Lacoursiere R, Badawi H, et al. Torque expression in stainless steel  
581 orthodontic brackets. A systematic review. Angle Orthod. 2010 Jan;80(1):201-10. doi:  
582 10.2319/080508-352.1. PubMed PMID: 19852662.
- 583 86. Contreras-Ochoa CO, Lagunas-Martinez A, Belkind-Gerson J, et al. Toxoplasma gondii  
584 invasion and replication in astrocyte primary cultures and astrocytoma cell lines: systematic

- 585 review of the literature. *Parasitol Res.* 2012 Jun;110(6):2089-94. doi: 10.1007/s00436-012-  
586 2836-7. PubMed PMID: 22314782.
- 587 87. Tong M, Viall CA, Chamley LW. Antiphospholipid antibodies and the placenta: a systematic  
588 review of their in vitro effects and modulation by treatment. *Hum Reprod Update.* 2015 Jan-  
589 Feb;21(1):97-118. doi: 10.1093/humupd/dmu049. PubMed PMID: 25228006.
- 590 88. Peplow PV, Chatterjee MP. A review of the influence of growth factors and cytokines in in  
591 vitro human keratinocyte migration. *Cytokine.* 2013 Apr;62(1):1-21. doi:  
592 10.1016/j.cyto.2013.02.015. PubMed PMID: 23490414.
- 593 89. Nawafleh N, Hatamleh M, Elshiyab S, et al. Lithium Disilicate Restorations Fatigue Testing  
594 Parameters: A Systematic Review. *J Prosthodont.* 2016 Feb;25(2):116-26. doi:  
595 10.1111/jopr.12376. PubMed PMID: 26505638.
- 596 90. Tsouh Fokou PV, Nyarko AK, Appiah-Opong R, et al. Ethnopharmacological reports on anti-  
597 Buruli ulcer medicinal plants in three West African countries. *J Ethnopharmacol.* 2015 Aug  
598 22;172:297-311. doi: 10.1016/j.jep.2015.06.024. PubMed PMID: 26099634.
- 599 91. Ethem Yaylali I, Keceli AD, Ureyen Kaya B. Ultrasonically Activated Irrigation to Remove  
600 Calcium Hydroxide from Apical Third of Human Root Canal System: A Systematic Review of  
601 In Vitro Studies. *J Endod.* 2015;41(10):1589-99. doi: 10.1016/j.joen.2015.06.006.
- 602 92. Samiei M, Farjami A, Dizaj SM, et al. Nanoparticles for antimicrobial purposes in  
603 Endodontics: A systematic review of in vitro studies. *Mater Sci Eng C Mater Biol Appl.*  
604 2016;58:1269-78. doi: 10.1016/j.msec.2015.08.070.
- 605 93. Xia L, Xu J, Guzzo TJ. Reporting and methodological quality of meta-analyses in urological  
606 literature. *PeerJ* 2017;5(e3129).
- 607 94. Gagnier JJ, Kellam PJ. Reporting and methodological quality of systematic reviews in the  
608 orthopaedic literature. *J Bone Joint Surg Am.* 2013;95(11):e771-7.
- 609 95. Liu Y, Zhang R, Huang J, et al. Reporting quality of systematic reviews/meta-analyses of  
610 acupuncture. *PLoS One.* 2014;9(11):e113172.
- 611 96. Willis BH, Quigley M. The assessment of the quality of reporting of meta-analyses in  
612 diagnostic research: a systematic review. *BMC Med Res Methodol.* 2011;11:163.
- 613 97. Cullis PS, Gudlaugsdottir K, Andrews J. A systematic review of the quality of conduct and  
614 reporting of systematic reviews and meta-analyses in paediatric surgery. *PLoS One*  
615 2017;12(4):e0175213.
- 616 98. Fleming PS, Seehra J, Polychronopoulou A, et al. A PRISMA assessment of the reporting  
617 quality of systematic reviews in orthodontics. *Angle Orthod.* 2013;83(1):158-63.
- 618 99. Peters JP, Hooft L, Grolman W, et al. Reporting Quality of Systematic Reviews and Meta-  
619 Analyses of Otorhinolaryngologic Articles Based on the PRISMA Statement. *PLoS One.*  
620 2015;10(8):e0136540.
- 621 100. Wasiak J, Tyack Z, Ware R, et al. Poor methodological quality and reporting standards of  
622 systematic reviews in burn care management. *Int Wound J.* 2016.
- 623 101. Tan WK, Wigley J, Shantikumar S. The reporting quality of systematic reviews and meta-  
624 analyses in vascular surgery needs improvement: a systematic review. *Int J Surg.*  
625 2014;12(12):1262-5.
- 626 102. Tian J, Zhang J, Ge L, et al. The methodological and reporting quality of systematic reviews  
627 from China and the USA are similar. *J Clin Epidemiol* 2017;pii: S0895-4356(16):30816-2.
- 628 103. Fleming PS, Koletsi D, Pandis N. Blinded by PRISMA: Are Systematic Reviewers Focusing on  
629 PRISMA and Ignoring Other Guidelines? *PLoS One.* 2014;9(5):e96407.

630

631

632 **Figure legend**

633 Figure 1. Flowchart of the search strategy of this systematic review of *in vitro* studies -  
634 Summary of how the systematic search was conducted and eligible studies were identified  
635 (PRISMA flow diagram). PRISMA = Preferred Reporting Items for Systematic reviews and  
636 Meta-Analyses.

637 Figure 2. Scatter plot showing the relationship between the overall score and journal's impact  
638 factor (IF) - Spearman's rho test indicated positive correlation but not significantly between  
639 the overall quality score and IF,  $r = 0.209$ .

640 Figure 3. Trend of SR of *in vitro* studies and overall quality score over the year- A- The  
641 number of SRs of *in vitro* studies published per year. B- Regression analysis revealed the  
642 trend of overall quality score was not significantly increasing over years (coefficient of  
643 correlation  $\beta = 0.11$ ,  $p = 0.363$ ).

644